Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab-Reference-Cited by-同舟云学术

Early C-reactive protein kinetics predict survival of patients with advanced urothelial cancer treated with pembrolizumab

Published:2020-09-02 Issue:3 Volume:70 Page:657-665
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Kijima Toshiki,Yamamoto Hina,Saito Kazutaka^ORCID,Kusuhara Shota,Yoshida Soichiro,Yokoyama Minato,Matsuoka Yoh,Numao Noboru,Sakai Yasuyuki,Matsubara Nobuaki,Yuasa Takeshi,Masuda Hitoshi,Yonese Junji,Kageyama Yukio,Fujii Yasuhisa

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

https://link.springer.com/content/pdf/10.1007/s00262-020-02709-2.pdf

Reference30 articles.

1. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376(11):1015–1026. https://doi.org/10.1056/NEJMoa1613683

2. Fradet Y, Bellmunt J, Vaughn DJ, Lee JL, Fong L, Vogelzang NJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970–976. https://doi.org/10.1093/annonc/mdz127

3. Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA et al (2011) Defining the critical hurdles in cancer immunotherapy. J Transl Med 9:214. https://doi.org/10.1186/1479-5876-9-214

4. Kim C, Prasad V (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: An analysis of 5 years of US food and drug administration approvals. JAMA Inter Med 175(12):1992–1994. https://doi.org/10.1001/jamainternmed.2015.5868

5. Chiou VL, Burotto M (2015) Pseudoprogression and immune-related response in solid tumors. J Clin Oncol 33(31):3541–3543. https://doi.org/10.1200/jco.2015.61.6870

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis;Immunotherapy;2024-08-19

2. Gustave Roussy Immune score as a prognostic biomarker in patients with platinum-refractory metastatic urothelial carcinoma treated with pembrolizumab: YUSHIMA study;International Journal of Clinical Oncology;2024-06-04

3. C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study;Cancers;2024-04-28

4. Tumor-associated neutrophils suppress CD8+ T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis;British Journal of Cancer;2024-01-17

5. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review;Japanese Journal of Clinical Oncology;2023-12-18